Other Assets

AX-LAH3 MAb

iQur’s VLP platform technology can also be utilised to generate monoclonal antibodies against epitopes which are otherwise difficult to target because they are cryptic or non-immunogenic.

We have harnessed VLP presentation to overcome these obstacles. This technology application was exemplified by generating a universal antibody to influenza A virus H3 hemagglutinin that recognises all strains within the H3 subtype variants of this important protein. The resulting monoclonal antibody cell line (AX-LAH3) was made available to virology researchers through the NIH associated BEI Resources repository managed by ATCC. This repository was established by the National Institute of Allergy and Infectious Diseases (NIAID) to provide reagents, tools and information for studying Category A, B and C priority pathogens, emerging infectious disease agents, non-pathogenic microbes and other microbiological materials of relevance to the research community. Monoclonal antibodies are important reagents that scientists need to carry out basic research and develop improved diagnostic tests, vaccines and therapies.

Share by: